SRLS Seracare Life Sciences (MM)

Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of SeraCare Life Sciences, Inc. (NASDAQ: SRLS) arising from its agreement for the Company and its subsidiaries to be acquired by an affiliate of Linden Capital Partners, a private equity firm, for $4.00 per SeraCare share.

Weiss & Lurie is investigating whether SeraCare’s Board acted in the best interests of SeraCare shareholders in approving this deal. Notably, prior to the announcement of the deal, the two analysts following the Company had set its price target at $5.00 per share. Indeed, according to SeraCare’s February 10, 2012 press release announcing its financial results for its 2012 first fiscal quarter results, the Company experienced revenue growth of 9% as compared with the same quarter in the prior year and it “continues to generate strong cash flow and maintain a healthy balance sheet with $19.5 million in cash and virtually no debt.”

If you own SeraCare shares and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Julia J. Sun either by email at info@weisslurie.com or by telephone at (888) 593-4771.

Weiss & Lurie has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at info@weisslurie.com or fill out the form on our website, http://www.weisslurie.com/contact/report_fraud/.

Attorney Advertising. Past results do not guarantee a similar outcome.

Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024